Business
Reconfirmation of Market Guidance and AGM Q&A
SkinBioTherapeutics plc has confirmed that its trading for the new financial year has started positively and anticipates reporting full-year 2026 results in line with market expectations, which include revenue of £6.2 million and adjusted EBITDA of £0.7 million. The company also provided a Q&A for shareholders regarding the upcoming Annual General Meeting. Disclaimer*
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n\n\n \nSkinBioTherapeutics plc (\"SkinBioTherapeutics\" or the \"Group\" or the \"Company\")\n \nReconfirmation of Market Guidance and AGM Shareholder Information\n \n18 December 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science group focused on skin health, confirms that overall trading of the Group has started very positively for the new financial year. Consequently, the Board still anticipates reporting 2026 full year numbers in line with market expectations*.\nIn addition, in response to some shareholder questions about the upcoming AGM, the Directors have provided a Q&A within the Shareholder Circulars section of the Shareholder Information page [Here].\n* Market expectations for the year ending 30 June 2026: revenue of £6.2 million and adjusted EBITDA of £0.7 million\n \n-Ends-\n \nFor more information please contact:\n\n\n\n\nSkinBioTherapeutics plc\nStuart J. Ashman, CEO\nEmily Bertram, Group Finance Director\n\n\n+44 (0) 191 495 7325\n \n\n\n\n\nSinger Capital Markets (Nominated Adviser & Broker)\nPhilip Davies\nJames Todd\nPatrick Weaver\n\n\n+44 (0) 020 7496 3000\n \n\n\n\n\nVigo Consulting (financial press)\nRozi Morris, Melanie Toyne-Sewell\n \n\n\n+44 (0) 20 7390 0230\[email protected]\n \n\n\n\n\nNotes to Editors\nAbout SkinBioTherapeutics plc\nSkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.\nThe Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.\nThe Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufac...